<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887913</url>
  </required_header>
  <id_info>
    <org_study_id>Matrix RF_Facial Tx</org_study_id>
    <nct_id>NCT00887913</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Performance of Fractional Radiofrequency for Improvement of Skin Texture Via Skin Resurfacing and Wrinkles Reduction</brief_title>
  <official_title>Clinical Study to Evaluate the Performance of Fractional Radiofrequency for Improvement of Skin Texture Via Skin Resurfacing and Wrinkles Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syneron Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Syneron Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the Matrix RF applicator is effective in
      the treatment of facial skin texture and wrinkle reduction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Fine Lines</measure>
    <time_frame>4 week follow up after last treatment</time_frame>
    <description>Improvement of fine lines (wrinkles) assessed per anatomical area treated based on Improvement Scale: 0-4 where higher scores indicate a better outcome.
Improvement is graded by means of photographs taken at baseline vs treatment 3 and baseline vs 6week follow up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in Smoothness</measure>
    <time_frame>4 weeks follow up post last treatment</time_frame>
    <description>Smoothness of anatomical treated area assessed based on Improvement Scale 0-4.Where higher scores indicate a better outcome.
Improvement is graded by means of photographs taken at baseline vs treatment 3 and baseline vs 6week follow up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in Brightness</measure>
    <time_frame>4 week follow up post last treatment</time_frame>
    <description>Assess the improvement in brightness of the treated anatomical area using Improvement Scale where higher scores indicate a better outcome.
Improvement is graded by means of photographs taken at baseline vs treatment 3 and baseline vs 6week follow up</description>
  </primary_outcome>
  <enrollment type="Actual">69</enrollment>
  <condition>Skin Resurfacing</condition>
  <condition>Wrinkle Reduction</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fractional RF treatment with Matrix RF applicator</intervention_name>
    <description>3 treatments, single pass, 2-50J</description>
    <other_name>Matrix RF Applicator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent agreement signed by the subject.

          -  Healthy males or females older than 21 years of age.

          -  Having at least two facial sub-areas with visible lines/wrinkles and elastosis, which
             correlate to a score of 2 6 on the Fitzpatrick Classification of Wrinkling and Degree
             of Elastosis.

          -  Fitzpatrick skin type I-VI (note: skin type VI should not undergo treatment using
             resurfacing procedure parameters).

          -  Willingness to follow the treatment and follow-ups schedule and the post-treatment
             care.

          -  For female candidates - post-menopausal or surgically sterilized, or using a medically
             acceptable form of birth control at least 3 months prior to enrollment and during the
             entire course of the study (i.e., oral contraceptives, IUD, contraceptive implant,
             barrier methods with spermicide, or abstinence).

        Exclusion Criteria:

          -  Pregnant or planning to become pregnant, having given birth less than 3 months ago,
             and/or breastfeeding.

          -  Having any active electrical implant anywhere in the body, such as a pacemaker or an
             internal defibrillator.

          -  Having a permanent implant in the treated area, such as metal plates and screws, or an
             injected chemical substance.

          -  Having a history of diseases stimulated by heat, such as recurrent Herpes Simplex in
             the treated area, unless treatment is conducted following a prophylactic regimen.

          -  Having received acne treatment with a light-based device within 1 month of treatment
             or during the study.

          -  Use of isotretinoin (AccutaneÂ®) within 6 months of treatment or during the study.

          -  Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen-containing
             agents) one week before and after each treatment session.

          -  Use of retinoids, antioxidants or skin nourishing supplements within 2 months of
             treatment or during the study.

          -  Having received a facial dermabrasion or chemical peel treatment within 3 months of
             treatment or during the study.

          -  Having received treatment with light, RF or other devices in the treated area within 6
             months of treatment or during the study.

          -  Having received Botox/collagen/fat injections or other methods of augmentation with
             injected or implanted material in the treated area within 9 months of treatment or
             during the study.

          -  Having undergone a resurfacing procedure, face lift or eyelid surgery within a year of
             treatment or during the study.

          -  Having undergone any other surgery in the treated area within 6 months of treatment
             (or more if skin has not healed completely) or during the study.

          -  History of keloid scarring or of abnormal wound healing.

          -  Suffering from current or history of significant skin conditions in the treated area
             or inflammatory skin conditions, including, but not limited to: excessive skin
             dryness, psoriasis, eczema, rash, rosacea (particularly severe open wound stage),
             indurate acne, varicella scars, open lacerations or abrasions and active cold sores or
             herpes sores prior to treatment (duration of resolution as per the Investigator's
             discretion) or during the treatment course.

          -  History of immunosuppression/immune deficiency disorders (including HIV infection or
             AIDS) or currently using immunosuppressive medications.

          -  History of epidermal or dermal disorders (particularly if involving collagen or
             microvascularity).

          -  History of pigmentary disorders, particularly tendency for hyper- or
             hypo-pigmentation.

          -  Suffering from hormonal imbalance, as per the Investigator's discretion.

          -  Having a known anticoagulative or thromboembolic condition or taking anticoagulation
             medications one week prior to and during the treatment course (to allow inclusion,
             temporary cessation of use as per the subject's physician discretion).

          -  Having or undergoing any form of treatment for active cancer, or having a history of
             skin cancer or any other cancer in the areas to be treated, including presence of
             malignant or pre-malignant pigmented lesions.

          -  Suffering from significant concurrent illness, such as cardiac disorders, diabetes
             (type I or II), or pertinent neurological disorders.

          -  Vascular lesion, tattoo or permanent make-up in the treated area.

          -  Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning
             during the study.

          -  Participation in a study of another device or drug within one month prior to
             enrollment or during the study.

          -  As per the Investigator's discretion, any physical or mental condition which might
             make it unsafe for the subject to participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Advanced Dermatology</name>
      <address>
        <city>Lincolnshire</city>
        <state>Illinois</state>
        <zip>60069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser and Dermatology Surgery Center</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laserderm</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Z 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2009</study_first_posted>
  <results_first_submitted>October 6, 2010</results_first_submitted>
  <results_first_submitted_qc>November 2, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 30, 2010</results_first_posted>
  <last_update_submitted>November 2, 2010</last_update_submitted>
  <last_update_submitted_qc>November 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Yehudit Kraizer</name_title>
    <organization>Syneron Medical</organization>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Treatment group- undergo 3 treatments every 4-6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Treatment group- undergo 3 treatments every 4-6 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.02" spread="8.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Fine Lines</title>
        <description>Improvement of fine lines (wrinkles) assessed per anatomical area treated based on Improvement Scale: 0-4 where higher scores indicate a better outcome.
Improvement is graded by means of photographs taken at baseline vs treatment 3 and baseline vs 6week follow up</description>
        <time_frame>4 week follow up after last treatment</time_frame>
        <population>Per protocol each defined anatomical area treated was assessed for improvement according to Improvement Scale- 0-4</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Treatment group- undergo 3 treatments every 4-6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Fine Lines</title>
          <description>Improvement of fine lines (wrinkles) assessed per anatomical area treated based on Improvement Scale: 0-4 where higher scores indicate a better outcome.
Improvement is graded by means of photographs taken at baseline vs treatment 3 and baseline vs 6week follow up</description>
          <population>Per protocol each defined anatomical area treated was assessed for improvement according to Improvement Scale- 0-4</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Fine Lines</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Smoothness</title>
        <description>Smoothness of anatomical treated area assessed based on Improvement Scale 0-4.Where higher scores indicate a better outcome.
Improvement is graded by means of photographs taken at baseline vs treatment 3 and baseline vs 6week follow up</description>
        <time_frame>4 weeks follow up post last treatment</time_frame>
        <population>Analysis was per protocol, each area treated was graded on its improvement regarding the smoothness of the skin</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Treatment group- undergo 3 treatments every 4-6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Smoothness</title>
          <description>Smoothness of anatomical treated area assessed based on Improvement Scale 0-4.Where higher scores indicate a better outcome.
Improvement is graded by means of photographs taken at baseline vs treatment 3 and baseline vs 6week follow up</description>
          <population>Analysis was per protocol, each area treated was graded on its improvement regarding the smoothness of the skin</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Smoothness</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Brightness</title>
        <description>Assess the improvement in brightness of the treated anatomical area using Improvement Scale where higher scores indicate a better outcome.
Improvement is graded by means of photographs taken at baseline vs treatment 3 and baseline vs 6week follow up</description>
        <time_frame>4 week follow up post last treatment</time_frame>
        <population>Per protocol, each anatomical area treated was assessed for skin brightness using the Improvement Scale of 0-4 where 0= 0%, 1= 1-25%, 2=26-50%, 3=51-75%, 4= 76-100% based on before and photographs. Maximum value grade is 4 and the minimum value grade is 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Treatment group- undergo 3 treatments every 4-6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Brightness</title>
          <description>Assess the improvement in brightness of the treated anatomical area using Improvement Scale where higher scores indicate a better outcome.
Improvement is graded by means of photographs taken at baseline vs treatment 3 and baseline vs 6week follow up</description>
          <population>Per protocol, each anatomical area treated was assessed for skin brightness using the Improvement Scale of 0-4 where 0= 0%, 1= 1-25%, 2=26-50%, 3=51-75%, 4= 76-100% based on before and photographs. Maximum value grade is 4 and the minimum value grade is 0.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Brightness</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for the duration of the study, up to 5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Treatment group- undergo 3 treatments every 4-6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI is under a general confidentiality agreement and must have prior written approval by the Sponsor prior to publishing the study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hanit Brenner-Lavie</name_or_title>
      <organization>Syneron Medical Ltd</organization>
      <phone>972-73-244-2200 ext 581</phone>
      <email>hanitb@syneron.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

